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BACKGROUND: A growing body of research suggests that
statins improve perioperative cardiac outcomes by
attenuating inflammation. Conversely, some studies
suggest that withdrawal of statins after surgery results in an
upsurge of inflammation and adverse cardiac outcomes.
METHODS: We performed a literature search using multiple
medical databases to examine the basic, clinical, and
experimental evidence supporting the existence of a statin
withdrawal state. Studies examining outcomes associated
with statin withdrawal were narratively synthesized.
RESULTS: Published evidence suggests that statin
withdrawal is associated with worse cardiac outcomes in a
variety of scenarios, including acute coronary syndrome,
ischemic stroke, and surgery. Although certain reasons for
postoperative statin cessation are difficult to avoid (eg, ileus
after surgery), we posit that many perioperative clinicians
may be unaware of the importance of statin resumption in
a timely fashion. This lack of awareness translates into
preventable harm and an opportunity for outcome
improvement. We introduce innovative practices through
which perioperative practitioners may prevent statin
discontinuation.
CONCLUSIONS: Ensuring the resumption of statins after
surgery should become routine practice for perioperative
providers. We highlight knowledge gaps and identify a
research agenda aimed at better understanding this
practice. Journal of Hospital Medicine 2012;7:573–579.
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Accumulating evidence suggests that perioperative
treatment with 3-hydroxy-3-methylglutaryl coenzyme-
A (HMG-CoA) reductase inhibitors (or, ‘‘statins’’)
reduces the incidence of cardiovascular events during
noncardiac surgery.1–6 This evidence has lead the
European Society of Cardiology (ESC) and American
College of Cardiology Foundation/American Heart
Association (ACCF/AHA) to endorse the use of peri-
operative statins in patients already on this treatment
or those at high-risk of cardiovascular events.7,8
However, statins are available only in oral formula-
tion. Consequently, prolonged bowel recovery or clini-
cal instability may interfere with use during surgery.
Furthermore, many clinicians may not recognize the
imperative of postoperative statin resumption, viewing
them principally as lipid-lowering entities and not as
agents of perioperative benefit. Failure to resume sta-
tins postoperatively can be catastrophic, as the ensu-
ing inflammation and thrombosis frequently culmi-
nates in myocardial infarction (MI) or death.9,10
In this article, we review the potent anti-inflamma-
tory properties of statins and their role in preventing
perioperative cardiac events. We outline the biochemi-
cal basis for perioperative statin benefit, summarizing
the basic, clinical, and experimental evidence regard-
ing statin withdrawal. We conclude by presenting
strategies to avert postoperative statin cessation and
outline a research agenda dedicated to informing this
practice.
METHODS
We performed a literature search using MEDLINE via
Ovid (1946–present), EMBASE (1946–present), Biosis
(1926–present), and Cochrane CENTRAL (1960–pres-
ent). We used Boolean logic to search for key terms
including statins, 3-hydroxy-3-methylglutaryl CoA re-
ductase inhibitors, death, MI, stroke, acute coronary
syndrome (ACS), and statin withdrawal or cessation.
All studies published in full-text or abstract form were
included. A total of 489 articles were retrieved by this
search (last updated March 15, 2012). For this narra-
tive review, we focused on studies that examined
adverse outcomes associated with statin withdrawal.
BIOCHEMICAL BASIS OF STATIN
PLEIOTROPICITY
The non–lipid-lowering or ‘‘pleiotropic’’ properties of
statins are especially valuable in the perioperative
setting.1–6,11 Perioperative cardiac complications occur
due to oxygen supply:demand mismatch, vascular
inflammation, or a combination of these states. A sig-
nificant perisurgical catecholamine surge produces
unopposed sympathetic effects,12 increasing the risk of
rupture of vulnerable coronary plaques, thrombus for-
mation, and adverse cardiac events.13,14 Similarly,
augmented inflammatory responses and increased
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circulating coagulation factors further predispose to a
hazardous perioperative milieu.15 Statins attenuate
this vascular inflammatory response by suppressing
the synthesis of mevalonate by inhibiting HMG-CoA
reductase. Suppression of mevalonate synthesis
reduces the bioavailability of 2 important isoprenoid
molecules: farnesyl-pyrophosphate and geranylger-
anyl-pyrophosphate.16 Diminution of these isoprenoid
intermediaries leads to reductions in the active intra-
cellular signaling molecules Ras, Rho, and Rac, which
play critical roles in vascular reactivity, endothelial
function, and coagulation and inflammatory path-
ways.17–23 The cumulative effect of these cellular
changes is diminished inflammation during periods of
surgical stress (Figure 1).
While the perioperative pleiotropicity of statins is of
inherent clinical value, several studies have shown
that these effects are lost and even reversed when
statins are withdrawn.24–28 During statin treatment,
absence of isoprenoid intermediaries induces cytosolic
accumulation of nonactivated Rho and Rac proteins.
Abrupt cessation of statins activates Rho/Rac-kinase
pathways, leading to unregulated inflammation,
platelet hyper-activation, and endothelial dysfunc-
tion.24,25,28,29 For instance, statin withdrawal in mice-
models leads to an ‘‘overshoot’’ activation of Rho,
resulting in down-regulation of endothelial nitric ox-
ide production,25 activation of nicotinamide adenine
dinucleotide phosphate (NAD[P]H)-oxidase, and
increased superoxide production.29 In another mouse-
model, statin withdrawal was associated with up-regu-
lation of key pro-thrombotic molecules including pla-
telet factor 4 and beta-thromboglobulin.24 In human
studies, a platelet ‘‘hyper-activation state’’ (manifested
by increased platelet P-selectin expression and
enhanced platelet aggregation) occurs after statin dis-
continuation.27 Furthermore, withdrawal of statins in
patients with hyperlipidemia increases inflammatory
markers such as C-reactive protein and interleukin-
6.26 In the perioperative context, absence of these im-
portant anti-inflammatory properties increases the risk
of cardiac events.9,10
EVIDENCE SUGGESTING BENEFIT FROM
PERIOPERATIVE STATIN TREATMENT
Retrospective studies first suggested clinical benefit
from perioperative statin treatment. In a case-control
study involving 2816 patients undergoing vascular
surgery at Erasmus Medical Center, statin use was
associated with substantially decreased postoperative
mortality (adjusted odd ratio [OR] 0.22, 95% confi-
dence interval [CI] 0.10–0.47).5 In a subsequent
retrospective cohort study of 780,591 patients who
underwent major noncardiac surgery, the risk of post-
operative mortality was considerably lower among
statin users (unadjusted OR 0.68, 95% CI 0.64–0.72)
compared to patients who did not receive, or received
delayed treatment with statins.3 A third retrospective
study of 1163 vascular surgery patients found that
statins prevented perioperative cardiac complications
including death, MI, congestive heart failure, and ven-
tricular tachyarrhythmias (OR 0.52, 95% CI 0.35–
0.76).4
The benefit from statin treatment found in retro-
spective studies prompted the first double-blinded,
randomized controlled trial (RCT) of perioperative
statin use. In 2004, Durazzo and colleagues1 random-
ized 100 statin-naive patients scheduled to undergo
elective aortic, femoro-popliteal, or carotid surgery to
receive either 20 mg of atorvastatin or placebo for
45 days. Vascular surgery was performed, on average,
31 days after randomization. Atorvastatin therapy
reduced the incidence of death from cardiac causes,
FIG. 1. Pleiotropic effects of statins and statin withdrawal. Statins inhibit 3-
hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductase to prevent
mevalonate formation. Statin withdrawal reverses this phenomenon and up-
regulates inflammatory molecule production. Abbreviations: FPP, farnesyl-
pyrophosphate; GPP, geranyl-pyrophosphate; LDL, low-density lipoprotein.
Fallouh and Chopra | Statin Withdrawal After Major Surgery
574 An Official Publication of the Society of Hospital Medicine Journal of Hospital Medicine Vol 7 | No 7 | September 2012
nonfatal acute MI, ischemic stroke, and unstable an-
gina (26% in the placebo group vs 8% in the atorvas-
tatin group; P ¼ 0.031).1 Although the small size of
the trial rendered it underpowered to show a mortal-
ity benefit, this remains the first RCT to demonstrate
a protective perioperative effect of statins.
In the 2009 Dutch Echocardiographic Cardiac Risk
Evaluation Applying Stress Echocardiography
(DECREASE)-III trial, Schouten and colleagues6
randomized 497 high-risk, statin-naive patients under-
going vascular surgery to receive, in addition to a
beta-blocker, either fluvastatin or placebo before sur-
gery (median of 37 days). Postoperative myocardial is-
chemia (hazard ratio [HR] 0.55, 95% CI 0.34–0.88),
and combined death from cardiovascular causes or
nonfatal MI (HR 0.47, 95% CI 0.24–0.94), occurred
less frequently in the treatment group.6 In 2009, the
same group published DECREASE-IV, a multicenter,
prospective, open-label, 2  2 factorial design trial of
1066 intermediate-risk patients, scheduled to undergo
elective, noncardiac surgery. Patients were assigned to
bisoprolol, fluvastatin, combination treatment, or con-
trol therapy before surgery (median of 34 days).
Although those randomized to fluvastatin demon-
strated lower incidence of 30-day cardiac death and
MI than control (HR 0.65, 95% CI 0.35–1.10), these
outcomes failed to reach statistical significance as the
trial was principally powered to examine the effects of
perioperative beta-blockade.30
Using this pool of data, a meta-analysis of 15 stud-
ies (223,010 patients) found a substantial 38% reduc-
tion in the risk of mortality after cardiac surgery
(1.9% vs 3.1%; P ¼ 0.0001) and an even greater
59% reduction in the risk of mortality following vas-
cular surgery (1.7% vs 6.1%; P ¼ 0.0001) with peri-
operative statin therapy. When including noncardiac
surgery, a 44% reduction in mortality was observed
(2.2% vs 3.2%; P < 0.01).2 We performed a similar
meta-analysis of 15 RCTs involving 2292 patients to
determine whether perioperative statin treatment in
statin-naive patients, undergoing either cardiac or
noncardiac surgery, improved clinical outcomes. Our
analysis also found statistically significant reductions
in the risk of MI associated with perioperative statin
use in both cardiac and noncardiac surgery (risk
reduction [RR] 0.53, 95% CI 0.38–0.74) and atrial fi-
brillation in statin-naive patients undergoing cardiac
surgery (RR 0.56, 95% CI 0.45–0.69).31 Taken to-
gether, a large volume of evidence supports the use of
statins in surgical settings.
In view of this evidence, the ACCF/AHA periopera-
tive guidelines for noncardiac surgery endorsed statins
as an important risk-reducing intervention in those
undergoing noncardiac surgery, and recommended
continued use in patients on chronic statin treatment
scheduled for noncardiac surgery (Level of Evidence
B, Class I; Benefits >>> Risk). Initiating statins in
patients undergoing vascular surgery, with or without
risk factors, was considered reasonable (Level of Evi-
dence B, Class IIa; Benefits >> Risk).7 Current ESC
perioperative guidelines in noncardiac surgery offer
similar recommendations to those of ACCF/AHA, but
differ by categorizing the recommendation to initiate
statins in patients at high cardiovascular risk as a
Class I recommendation.8
CLINICAL CONSEQUENCES OF STATIN
WITHDRAWAL
Although statins provide important cardiac benefits,
an important limitation to their perioperative use
remains their oral-only formulation. Thus, patients
who are unable to resume oral intake may fail to
resume treatment. Perioperative statin cessation has
been hypothesized to lead to a ‘‘statin withdrawal’’
phenomenon. The evidence that supports the existence
of this phenomenon comes from 3 distinct popula-
tions: ACS, ischemic stroke, and perioperative patients
(Table 1).
Statin Withdrawal in Acute Coronary Syndromes
Several studies have demonstrated an association
between statin withdrawal and heightened risk of car-
diovascular events in ACS.32–34 In a retrospective
analysis of 1616 patients presenting with ACS, with-
drawal of statins during or after admission was associ-
ated with more frequent death and nonfatal MI com-
pared to those who continued therapy (OR 2.93, 95%
CI 1.64–6.27).33 In another retrospective observatio-
nal study of 68,606 non–ST-segment elevation MI
patients, statin cessation during the first 24 hours of
hospitalization was independently associated with
adverse outcomes including in-hospital death (adjusted
HR 1.83; 95% CI 1.58–2.13), cardiac arrest, and car-
diogenic shock.32 In a population-based, cohort study
in the United Kingdom, statin cessation following an
acute MI was independently associated with greater
all-cause mortality at 1-year (adjusted HR 1.88, 95%
CI 1.13–3.07).34
The significantly increased risk of adverse outcomes
associated with the interruption of statins in ACS may
be moderated by vascular inflammation related to the
inciting coronary event, as statin discontinuation in
patients with stable cardiac conditions was not associ-
ated with increased risk of cardiovascular events in a
large-scale, double-blind, parallel-group study.35
Statin Withdrawal in Ischemic Stroke
Adverse events associated with statin withdrawal have
also been reported in patients with cerebrovascular
disease. In a prospective observational study of 631
consecutive stroke survivors, those who discontinued
statins (owing to mild adverse effects or unclear rea-
sons) experienced increased mortality during the first
year after the event (adjusted HR 2.78, 95% CI 1.96–
3.72).36 Using a controversial study design aimed at
evaluating the effects of stopping oral intake
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(including chronic medications) during the first days
of acute stroke, Blanco and colleagues37 randomized
89 stroke victims on chronic statins to either continue
medications or experience statin withdrawal following
admission. Statin withdrawal was independently asso-
ciated with increased risk of mortality and depend-
ency at 3 months (OR 4.66, 95% CI 1.46–14.91).37
Perioperative Statin Withdrawal
In the perioperative setting, statin withdrawal has also
been associated with adverse outcomes. Using a quasi-
experimental design, Le Manach et al.9 evaluated the
risk of cardiac complications after infra-renal aortic
surgery when immediate, postoperative resumption of
statins was adopted at their institution. The investiga-
tors compared the risk of developing MI, cardiac
death, or abnormal troponin release in 491 patients
who did not get early postoperative statin resumption
(pre-intervention group) to 178 patients who did. Sta-
tin withdrawal for 4 days was demonstrated to be an
independent predictor of postoperative troponin leak
and MI (OR 2.9, 95% CI 1.6–5.5). Similarly,
Schouten et al.10 investigated the risk of adverse
events related to interruption of long-term statins by
examining cardiac outcomes in 298 statin users under-
going major vascular surgery. Among the 70 patients
who experienced statin withdrawal, an increased risk
of postoperative troponin release (HR 4.6, 95% CI
2.2–9.6), and the composite endpoint of MI and car-
diovascular death (HR 7.5, 95% CI 2.8–20.1), was
observed compared to those who resumed treatment.
Not unexpectedly, the most common reason for statin
cessation was inability to take oral medications after
surgery. However, even in patients who discontinued
statins, the use of extended-release fluvastatin was
associated with fewer perioperative cardiac events
than other statins. Furthermore, extended-release flu-
vastatin was also held for 2 days following surgery
(owing to inability to take the drug orally), in 25% of
patients in the DECREASE-III study. However, no
impact in the rate of adverse outcomes was noted de-
spite this interruption (OR 1.1, 95% CI 0.48–2.52).6
Although the authors surmised that the extended for-
mulation of fluvastatin had provided sustained levels
of statin activity despite lack of timely oral intake, it
is important to note that this theory may not be gen-
eralizable to chronic statin users, as they were not en-
rolled in this study. Conversely, some patients may
have experienced postoperative ileus for longer than 2
days, perhaps resulting in confounding or attenuation
of the effect noted in the study.
CLINICAL INSIGHTS INTO FAILURE OF
POSTOPERATIVE STATIN RESUMPTION
We hypothesize that failure to resume perioperative
statins may occur for 4 cardinal reasons. First,
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clinically challenging when complications such as
postoperative ileus, nausea, and vomiting peak. To
date, no intravenous statin formulations are available,
although phase-I studies are currently underway.38
Second, it is not inconceivable that perioperative clini-
cal instability may overshadow the resumption of sta-
tin treatment. Third, clinicians may also remain con-
cerned regarding adverse effects of statins, a thought
compounded by US Food and Drug Administration
statin package inserts that specifically advocate for
statins to be withheld during surgery. However,
although the occurrence of elevated liver function tests
and myopathy are theoretically important, the over-
whelming majority of perioperative statin studies in
noncardiac surgery have not found this to be a major
occurrence.39 Nonetheless, a lack of uniform defini-
tions and appropriate surveillance for adverse events
are important limitations to this finding. In our recent
systematic review, we were unable to provide refined
estimates of these important side effects owing to
differences in definition, variations in screening, and
absence of standardized cutoffs used in studies.31
Finally, an important reason for failing to resume
postoperative statins is that many physicians simply
fail to recognize the perioperative importance of these
agents.
STRATEGIES TO IMPROVE PERIOPERATIVE
STATIN RESUMPTION
Using the existing evidence, we propose the following
4 clinical strategies to assist in avoiding a statin with-
drawal state.
Nasogastric Administration
Utilizing a post-pyloric nasogastric tube is a straight-
forward solution to provide statins in those who can-
not otherwise tolerate oral intake due to nausea or
emesis. Although this solution is hardly innovative, it
is relevant as it forces consideration of the need to re-
sume postoperative statins by available means. While
the development of a high nasogastric output or a
prolonged ileus may limit the applicability of this
intervention, it is important that this option be consid-
ered as opposed to expectant watching for the clinical
return of bowel function. Simvastatin, atorvastatin,
rosuvastatin, and pravastatin can be crushed and
delivered through this route.40
Development of Reminder Systems
Computerized reminder systems have proved impor-
tant in ensuring the resumption of deep venous throm-
bosis prophylaxis and other preventative care compli-
ance in hospitalized patients.41,42 Using this process,
pharmacist- or electronic health record-based re-
minder systems could be implemented to ensure that
statins are restarted when clinically feasible. Further
studies are needed to test whether this approach can
lead to improved outcomes.
Medication Reconciliation Prior to Hospital
Discharge
Statin withdrawal highlights the pertinence of a ro-
bust, medical reconciliation process prior to the
patient’s departure from the hospital. In this context,
the development of policies using single- or multi-fac-
eted interventions that promote cooperation between
FIG. 2. Clinical strategies to prevent statin withdrawal. Abbreviations: GI, gastrointestinal; NPO, nil per os (nothing by mouth); OR, operating room.
Statin Withdrawal After Major Surgery | Fallouh and Chopra
An Official Publication of the Society of Hospital Medicine Journal of Hospital Medicine Vol 7 | No 7 | September 2012 577
inpatient physicians, surgeons, and pharmacists with
outpatient primary care providers are necessary.43
Preoperative Transition to Extended Release Statin
Formulations
An innovative approach to minimizing statin with-
drawal involves preoperative transition to an
extended-release statin formulation. This strategy may
be of particular value in patients where prolonged
bowel nonavailability is likely, such as those under-
going gastrointestinal surgery, or when prolonged
postoperative dietary restriction (eg, NPO [nil per os]:
nothing by mouth) status is expected (Figure 2).
CONCLUSIONS AND FUTURE DIRECTIONS
Sudden withdrawal of perioperative statins results in
adverse clinical outcomes. Individuals engaged in the
care of patients during surgery such as hospitalists,
anesthesiologists, and surgeons must become more
cognizant of a statin withdrawal state.
An important limitation associated with the study of
perioperative statin withdrawal remains the ambiguity
regarding the extent of the problem in the United
States. Therefore, a logical first step could be the use
of infrastructure within the National Surgical Quality
Improvement Program (NSQIP) to understand the epi-
demiology of perioperative statin use and consequen-
ces associated with statin discontinuation.44 Mandat-
ing such quality reporting could easily be built into
current NSQIP performance metrics. These data
would help inform a research agenda targeting
patients that experience statin withdrawal and strat-
egies most likely to prevent it.
Disclosure: Nothing to report.
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